Methods and compositions for determining heart failure or a risk of heart failure
View Patent ↗The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.
1. A method of determining increased risk of chronic heart failure in a subject, the method comprising: providing a biological sample from a human subject; determining an expression profile in said sample by amplifying nucleic acid sequences comprising SEQ ID NOS: 4 and 13, wherein said amplification comprises contacting said biological sample with a forward primer comprising a nucleic acid of SEQ ID NO: 64; comparing said expression profile to a reference expression profile comprising expression levels of SEQ ID NOS: 4 and 13 in at least one biological sample from at least one control subject; detecting an increase in the level of SEQ ID NOS: 4 and 13 in said biological sample compared to said reference expression profile; and determining increased risk of chronic heart failure in the human subject based on detecting an increase in the level of SEQ ID NOs: 4 and 13.
2. The method of claim 1 , further comprising detecting an increase in the level of a nucleic acid comprising SEQ ID NO: 3 in said biological sample compared to said reference expression profile, and determining an increased risk of chronic heart failure in the human subject based on detecting an increase in the level of SEQ ID NO: 3, wherein said reference expression profile comprises an expression level of SEQ ID NO: 3 in the at least one biological sample from the at least one control subject.
3. The method of claim 1 , wherein said biological sample is a serum sample.
4. The method of claim 1 , wherein the nucleic acid amplification method is real-time PCR, said PCR comprising forward and reverse primers.
5. The method of claim 4 , wherein the real-time PCR method further comprises a probe.
6. The method of claim 5 , wherein the probe comprises a nucleic acid sequence that is complementary to a sequence comprising any one of SEQ ID NOS: 4 and 13.
7. The method of claim 5 , wherein the probe comprises a nucleic acid sequence comprising any one of SEQ ID NOS: 73 and 82.
8. The method of claim 4 , wherein the reverse primer comprises a nucleic acid sequence comprising SEQ ID NO: 8.
9. The method of claim 1 , further comprising managing subject treatment based on the heart disease status.
10. The method of claim 9 , wherein managing subject treatment is selected from ordering further diagnostic tests, administering at least one therapeutic agent, surgery, and taking no further action.
11. The method of claim 1 , said method comprising further detecting a decrease in the level of a nucleic acid comprising any one of SEQ ID NOS: 40, 100 and 108 in said biological sample compared to said reference expression profile, wherein said reference expression profile comprises an expression level of the any one of SEQ ID NOs: 40, 100 and 108 in the at least one biological sample from the at least one control subject.
12. The method of claim 11 , further comprising determining increased risk of chronic heart failure based on detecting a decrease in the level of the at least one nucleic acid comprising any one of SEQ ID NOS: 40, 100, and 108 in said biological sample compared to said reference expression profile.